Medical technology group, Jomed, has seen sales increase sharply over the first half of the year. Turnover between January and June shot up by 51 per cent to SFr46 million ($27 million).
Operating profit at the Zurich-based group more than doubled at SFr6.8 million, with net profit tripling to SFr4 million.
"In addition to strong growth in Europe, the Japanese market is progressing very well and has seen a continual climb in sales," the company said in a statement.
The company was launched on the SWX New Market in April, and took its first step into the United States market in May when it bought New York-based MediDyne.
On Monday, Jomed, announced it intended to further strengthen its position in the US by buying Endosonics of California, a leading manufacturer of products used in ultrasound technology. Most of the purchase will be funded through a new stock offer on the Swiss exchange.
Jomed specialises in products for minimally invasive therapy and interventional cardiology.
by Tom O'Brien
In compliance with the JTI standards